

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Wah Yan Healthcare Limited

中國華仁醫療有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 648)

UPDATE ON CONDITIONS FOR RESUMPTION OF TRADING

Reference is made to the announcement of China Wah Yan Healthcare Limited (the “Company”) dated 31 July 2018, among other things, relating to the conditions for the resumption of trading in the shares of the Company. Unless otherwise defined, capitalized terms used in this announcement shall adopt the same meaning as those defined in the said announcement.

On 1 December 2020, the Company was advised by the Stock Exchange that, as an additional Resumption Condition, the Company is required to demonstrate compliance with Rule 13.24 of the Listing Rules.

The Stock Exchange may modify the Resumption Conditions and/or impose further conditions as the Company’s circumstances change.

GENERAL

Trading in the shares of the Company will continue to be suspended pending fulfilment of the Resumption Conditions. The Company will keep its shareholders and potential investors posted of any material development as and when appropriate.

Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

For and on behalf of the board of
China Wah Yan Healthcare Limited
Lam Sung Him Gaston
Company Secretary

Hong Kong, 4 December 2020

As at the date of this announcement, the board of directors of the Company comprises Mr. Chan Ka Chung, Mr. Cheung Wai Kwan and Mr. Wang Jianguo as executive directors; and Mr. Chan Yee Ping, Michael, Ms. Hu Xuezhen, Mr. Lam Chun Ho and Mr. Tsang Hung Kei as independent non-executive directors.